A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NCT05984602 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Canakinumab
DRUG: Tislelizumab
DRUG: Nab-Paclitaxel
DRUG: Gemcitabine

Sponsor

NYU Langone Health